A Phase 3 interventional study of Cyclophosphamide and Bortezomib in Amyloidosis, sponsored by Janssen Research & Development, LLC. Completed at 140 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-26.
Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 141 studies in Amyloidosis with a site in United States — 39 open to participants now, 47 under way, 10 of them phase 3. Amyloidosis · United States.
Among the 141 studies in Amyloidosis with a site in United States, this one is the 13th largest by enrollment of the 99 interventional ones that give a count, is one of 6 that started in 2017, is one of 27 in phase 3, and was the 62nd registered.
290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.
Browse Amyloidosis studies →39 of the 141 studies in Amyloidosis with a site in United States are open now. Recruiting first, the newest first:
Brigham and Women's Hospital · Sites in United States
Ages 18+
Eidos Therapeutics, a BridgeBio company · Sites in United States
Ages 18–80
GlaxoSmithKline · Sites in United States, Australia, United Kingdom
Ages 18+
Alnylam Pharmaceuticals · Sites in United States, Argentina, Australia and 19 more countries
Ages 18–85
Alnylam Pharmaceuticals · Sites in United States, Germany, Japan
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
141 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 46 · Phase 3 31 · Phase 4 3
First in 1979; this study’s year is marked. 6 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 416 is above the median of 46 across 189 interventional studies indexed under Amyloidosis.
Median enrollment 45 across the 99 interventional studies, 107 across the 41 observational. Of the 84 that completed or were terminated, 44 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
66 of 141 have an industry lead sponsor. The 10 most frequent:
This study is registered under Janssen Research & Development, LLC, one of the names counted as Johnson & Johnson. Under that name alone:
Janssen Research & Development, LLC is the lead sponsor of 932 studies on the registry; 76 are open to participants now.
Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.
Johnson & Johnson has 3 studies filed under Amyloidosis — fewer than ten, so there is no comparison to draw.
18 of the studies in Amyloidosis with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05619302Phase 3Brigham and Women's HospitalMolecular Imaging of Myocardial Fibrosis in Cardiac Amyloidosis | 2026-12-31 |
| NCT07560306Phase 3Brigham and Women's Hospital[64Cu]FBP8 PET for Early Detection of Intracardiac Thrombus in Amyloid Cardiomyopathy | 2027-03-30 |
| NCT06097832Nexcella Inc.Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis | 2026-12 |
| NCT05951816University of Tennessee Graduate School of MedicineA Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis | 2026-12 |
| NCT07196839University of Texas Southwestern Medical CenterDetermining the Association of TTR Stabilizing Therapy With Circulating TTR Amyloid Aggregates Over Time in Patients With ATTR-CM: Longitudinal Biomarker Study | 2026-12 |
Add all 18 to your calendar (.ics) → With an account.
Among the 141 studies in Amyloidosis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone (CyBorD) compared with CyBorD alone in treatment of newly diagnosed amyloid light chain (AL) amyloidosis participants.
Participant involved in study for approx. 8 years duration includes Screening Phase (complete clinical evaluation will be done), Treatment Phase (monitoring of adverse events (AEs), laboratory abnormalities and clinical response), Post-Treatment Observation Phase (disease evaluations will be done) and a Long-term Follow-up Phase (Subsequent anticancer treatment, response to subsequent treatment, date of progression and survival status will be obtained every 16 weeks).The primary hypothesis is that daratumumab in combination with CyBorD will improve the overall complete hematological response rate compared to CyBorD alone in AL amyloidosis participants. Safety will be assessed by AEs, laboratory test results, electrocardiogram, vital sign measurements, physical examination, and Eastern Cooperative Oncology Group (ECOG) performance status.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
of amyloid light-chain (AL) amyloidosis as defined by at least one of the following:
Exclusion Criteria:
Evidence of significant cardiovascular conditions as specified below:
Any one of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive dexamethasone (40 milligrams \[mg\] orally or intravenous \[IV\] dose), followed by cyclophosphamide (300 milligram per meter square \[mg/m\^2\] orally or IV dose), then bortezomib (1.3 mg/m\^2 subcutaneous injection) weekly on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles.
Drug: Cyclophosphamide · Drug: Bortezomib · Drug: Dexamethasone, 40 mg
Participants will receive dexamethasone (20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing) followed by 1800 mg of daratumumab subcutaneously followed by cyclophosphamide (300 mg/m\^2 orally or IV dose weekly) and bortezomib (1.3 mg/m\^2 subcutaneous injection weekly) on Days 1, 8, 15, 22 in every 28-day cycle for a maximum of 6 cycles. Daratumumab will be administered weekly for the first 8 weeks (2 cycles), then every 2 weeks for 4 cycles (cycles 3-6), and then every 4 weeks until progression of disease or subsequent therapy for a maximum of 2 years.
Drug: Daratumumab
Participants will receive 300 mg/m\^2 of cyclophosphamide as an oral or IV dose.
Participants will receive 1.3 mg/m\^2 of bortezomib as an subcutaneous (SC) injection.
Participants of CyBorD alone arm will receive 40 mg dexamethasone orally or IV dose. Participants of CyBorD plus daratumumab arm will receive dexamethasone 20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing to make a total of 40 mg.
Participants will receive 1800 mg of daratumumab subcutaneously.
Percentage of Participants With Overall Complete Hematologic Response (CHR)
Overall CHR rate was defined as percentage of participants who achieved CHR, according to the International Amyloidosis Consensus Criteria. CHR: normalization of free light chain levels and ratio, negative serum, and urine immunofixation. If involved free light chain (iFLC) is less than (\<) upper limit of normal (ULN) and serum and urine Immunofixation electrophoresis (IFE) are negative, then neither a normal uninvolved free light chain (uFLC) level nor a normal free light chain (FLC) ratio are required for complete response (CR).
Time frame: Up to 2.4 years
Major Organ Deterioration Progression-Free Survival (MOD-PFS)
MOD-PFS was defined as duration from the date of randomization to either hematologic progression, or major organ deterioration (clinical manifestation of cardiac failure or renal failure), or death, whichever occurred first. Per international amyloidosis consensus criteria (IACC), hematologic progression was defined as satisfying any one of the following criteria: 1) From CHR, abnormal free light chain ratio (light chain must be double and \>ULN); 2) From CHR/VGPR/PR, 50 percent (%) increase in serum M-protein to \>0.5 grams per deciliter (g/dL) or 50% increase in urine M-protein to 200 milligrams (mg)/day; 3) free light chain increase of 50% to 100 milligrams (mg)/Liter (L).
Time frame: From date of first randomization (Day -3) upto 6.5 years
Overall Survival (OS)
Overall survival (OS) was measured from the date of randomization to the date of the participant's death.
Time frame: From date of first randomization (Day -3) up to 7.1 years
Organ Response Rate (OrRR) at 6 Months: Cardiac Response
The Organ Response Rate (OrRR) for heart was defined as the percentage of participants with baseline involvement of the heart who achieved a confirmed organ response in the heart. Cardiac response was defined as as a decrease of \>30% in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and greater than (\>)300 nanogram/Litre (ng/L).
Time frame: Month 6
Organ Response Rate (OrRR) at 6 Months: Renal Response
The OrRR for kidney was defined as the percentage of participants with baseline involvement of the kidney who achieved a confirmed renal response in the kidney. Renal response was defined as more than equal to (≥) 30% decrease in proteinuria or proteinuria decreased to \<0.5 grams (g)/24 hours in the absence of renal progression.
Time frame: Month 6
Organ Response Rate (OrRR) at 6 Months: Liver Response
The OrRR for liver was defined as the percentage of participants with baseline involvement of the liver who achieved a confirmed liver response in the liver. Liver response was defined as 50% decrease in abnormal alkaline phosphatase value.
Time frame: Month 6
Percentage of Participants Who Achieved Complete Hematologic Response (CHR) at 6 Months
CHR rate was defined as percentage of participants who achieved CHR, according to the International Amyloidosis Consensus Criteria. CHR: normalization of free light chain levels and ratio, negative serum, and urine immunofixation. If involved free light chain is \< ULN and serum and urine IFE are negative, then neither a normal uninvolved free light chain (uFLC) level nor a normal free light chain (FLC) ratio are required for Complete Response (CR).
Time frame: Month 6
Time to Complete Hematologic Response (CHR)
Time to CHR was defined as time between the date of randomization and first efficacy evaluation at which the participant has met all criteria for hematologic CR. CHR was primarily defined by negative immunofixation results and normalized free light chain (FLC) parameters.
Time frame: From date of first randomization (Day -3) up to 6.5 years
Time to Cardiac Response
Time to cardiac response was defined as the time between the date of randomization and the first efficacy evaluation at which the participant had cardiac response.
Time frame: From date of first randomization (Day -3) up to 6.5 years
Time to Liver Response
Time to liver response was defined as the time between the date of randomization and the first efficacy evaluation at which the participant had liver response.
Time frame: From date of first randomization (Day -3) up to 6.5 years
Time to Renal Response
Time to renal response was defined as the time between the date of randomization and the first efficacy evaluation at which the participant had renal response.
Time frame: From date of first randomization (Day -3) up to 6.5 years
Time to Subsequent Non-cross Resistant Anti-plasma Cell Therapy
Time to subsequent non-cross resistant anti-plasma cell therapy was defined as the time from the date of randomization to the start date of subsequent non-cross resistant, anti-plasma cell therapy.
Time frame: From date of first randomization (Day -3) up to 6.5 years
Duration of Complete Hematologic Response (CHR)
Duration of CHR was defined as the time between the date of initial documentation of CHR to the date of first documented evidence of hematologic progressive diseased. CHR was primarily defined by negative immunofixation results and normalized FLC parameters.
Time frame: From date of first randomization (Day -3) up to 6.5 years
Hematologic Very Good Partial Response (VGPR) or Better Rate
Hematologic VGPR or Better Rate was defined as percentage of participants who achieved hematologic Complete response (CR) or VGPR. VGPR was defined as the difference between involved iFLC and uFLC after treatment for baseline difference between iFLC and uFLC (dFLC) \>50 milligrams per liter (mg/L): Reduction in the dFLC \<40 mg/L. For Baseline dFLC \< 50 mg/L: more than (\>) 90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours. CR was negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \< 5% PCs in bone marrow.
Time frame: From date of first randomization (Day -3) up to 6.5 years
Change From Baseline in the European Organisation for Research and Treatment of Cancer - Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Fatigue
The EORTC-QLQ-C30 a 30-question tool was used to assess the overall quality of life (QoL) in cancer patients. It included 30 items resulting in 5 functional scales (physical, role, emotional, cognitive, and social functioning), 1 Global health status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall QoL. Scores were transformed to a 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms.
Time frame: Baseline (Day -28), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92 and 96
Change From Baseline in the Short Form Health Survey, Version 2, the Mental Component Summary, (SF-36v2 MCS)
The SF-36 Health Survey was a generic measure of health status. The SF-36 consisted of 36 questions that yield an eight-scale (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) profile of functional health and well-being, as well as 2 physical and mental health summary measures and a preference-based health utility index. The physical component summary (PCS), the mental component summary (MCS), and the 8 domain scores range from zero (0) to 100, with higher scores representing higher level of functioning.
Time frame: Baseline (Day -28), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92 and 96
Change From Baseline in EORTC QLQ-C30 Global Health Status Score
The EORTC-QLQ-C30 a 30-question tool was used to assess the overall QoL in cancer patients. It included 30 items resulting in 5 functional scales (physical, role, emotional, cognitive, and social functioning), 1 GHS scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall QoL. Scores were transformed to a 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms.
Time frame: Baseline (Day -28), Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48, 52, 56, 60, 64, 68, 72, 76, 80, 84, 88, 92 and 96
| Milestone | Run-In: Daratumumab Plus CyBorD | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|---|
| Started | 28 | 193 | 195 |
| Treated | 28 | 188 | 193 |
| Completed | 0 | 0 | 0 |
| Not completed | 28 | 193 | 195 |
| Withdrew: Death | 5 | 65 | 47 |
| Withdrew: Lost to follow-up | 0 | 6 | 0 |
| Withdrew: Withdrawal by subject | 3 | 23 | 8 |
| Withdrew: Sponsor's decision | 20 | 99 | 140 |
Overall CHR rate was defined as percentage of participants who achieved CHR, according to the International Amyloidosis Consensus Criteria. CHR: normalization of free light chain levels and ratio, negative serum, and urine immunofixation. If involved free light chain (iFLC) is less than (\<) upper limit of normal (ULN) and serum and urine Immunofixation electrophoresis (IFE) are negative, then neither a normal uninvolved free light chain (uFLC) level nor a normal free light chain (FLC) ratio are required for complete response (CR).
| percentage of participants | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|
| Percentage of Participants With Overall Complete Hematologic Response (CHR) | 18.1 (13.0 to 24.3) | 53.3 (46.1 to 60.5) |
MOD-PFS was defined as duration from the date of randomization to either hematologic progression, or major organ deterioration (clinical manifestation of cardiac failure or renal failure), or death, whichever occurred first. Per international amyloidosis consensus criteria (IACC), hematologic progression was defined as satisfying any one of the following criteria: 1) From CHR, abnormal free light chain ratio (light chain must be double and \>ULN); 2) From CHR/VGPR/PR, 50 percent (%) increase in serum M-protein to \>0.5 grams per deciliter (g/dL) or 50% increase in urine M-protein to 200 milligrams (mg)/day; 3) free light chain increase of 50% to 100 milligrams (mg)/Liter (L).
| months | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|
| Major Organ Deterioration Progression-Free Survival (MOD-PFS) | 30.23 (16.66 to 48.89) | NA (NA to NA) |
Overall survival (OS) was measured from the date of randomization to the date of the participant's death.
| Months | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|
| Overall Survival (OS) | NA (NA to NA) | NA (NA to NA) |
The Organ Response Rate (OrRR) for heart was defined as the percentage of participants with baseline involvement of the heart who achieved a confirmed organ response in the heart. Cardiac response was defined as as a decrease of \>30% in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels and greater than (\>)300 nanogram/Litre (ng/L).
| Percentage of participants | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|
| Organ Response Rate (OrRR) at 6 Months: Cardiac Response | 22.2 (15.1 to 30.8) | 41.5 (32.5 to 51.0) |
The OrRR for kidney was defined as the percentage of participants with baseline involvement of the kidney who achieved a confirmed renal response in the kidney. Renal response was defined as more than equal to (≥) 30% decrease in proteinuria or proteinuria decreased to \<0.5 grams (g)/24 hours in the absence of renal progression.
| Percentage of participants | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|
| Organ Response Rate (OrRR) at 6 Months: Renal Response | 27.4 (19.5 to 36.6) | 53.8 (44.4 to 63.1) |
The OrRR for liver was defined as the percentage of participants with baseline involvement of the liver who achieved a confirmed liver response in the liver. Liver response was defined as 50% decrease in abnormal alkaline phosphatase value.
| Percentage of participants | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|
| Organ Response Rate (OrRR) at 6 Months: Liver Response | 7.1 (0.2 to 33.9) | 40.0 (12.2 to 73.8) |
CHR rate was defined as percentage of participants who achieved CHR, according to the International Amyloidosis Consensus Criteria. CHR: normalization of free light chain levels and ratio, negative serum, and urine immunofixation. If involved free light chain is \< ULN and serum and urine IFE are negative, then neither a normal uninvolved free light chain (uFLC) level nor a normal free light chain (FLC) ratio are required for Complete Response (CR).
| Percentage of participants | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|
| Percentage of Participants Who Achieved Complete Hematologic Response (CHR) at 6 Months | 14.0 (9.4 to 19.7) | 50.3 (43.0 to 57.5) |
Time to CHR was defined as time between the date of randomization and first efficacy evaluation at which the participant has met all criteria for hematologic CR. CHR was primarily defined by negative immunofixation results and normalized free light chain (FLC) parameters.
| Days | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|
| Time to Complete Hematologic Response (CHR) | 85.00 (14.0 to 617.0) | 67.50 (8.0 to 879.0) |
Time to cardiac response was defined as the time between the date of randomization and the first efficacy evaluation at which the participant had cardiac response.
| Months | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|
| Time to Cardiac Response | 4.67 (0.9 to 25.5) | 3.84 (1.0 to 17.8) |
Time to liver response was defined as the time between the date of randomization and the first efficacy evaluation at which the participant had liver response.
| Months | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|
| Time to Liver Response | 10.61 (2.0 to 15.2) | 4.68 (1.0 to 22.6) |
Time to renal response was defined as the time between the date of randomization and the first efficacy evaluation at which the participant had renal response.
| Months | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|
| Time to Renal Response | 3.75 (0.9 to 42.2) | 1.91 (0.4 to 38.3) |
Time to subsequent non-cross resistant anti-plasma cell therapy was defined as the time from the date of randomization to the start date of subsequent non-cross resistant, anti-plasma cell therapy.
| Months | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|
| Time to Subsequent Non-cross Resistant Anti-plasma Cell Therapy | 11.30 (8.71 to 21.03) | NA (NA to NA) |
Duration of CHR was defined as the time between the date of initial documentation of CHR to the date of first documented evidence of hematologic progressive diseased. CHR was primarily defined by negative immunofixation results and normalized FLC parameters.
| Months | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|
| Duration of Complete Hematologic Response (CHR) | NA (56.74 to NA) | NA (NA to NA) |
Hematologic VGPR or Better Rate was defined as percentage of participants who achieved hematologic Complete response (CR) or VGPR. VGPR was defined as the difference between involved iFLC and uFLC after treatment for baseline difference between iFLC and uFLC (dFLC) \>50 milligrams per liter (mg/L): Reduction in the dFLC \<40 mg/L. For Baseline dFLC \< 50 mg/L: more than (\>) 90% reduction in serum M-protein plus urine M-protein \<100 mg/24 hours. CR was negative immunofixation on the serum and urine, and disappearance of any soft tissue plasmacytomas, and \< 5% PCs in bone marrow.
| Percentage of participants | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|
| Hematologic Very Good Partial Response (VGPR) or Better Rate | 50.3 (43.0 to 57.5) | 79.0 (72.6 to 84.5) |
The EORTC-QLQ-C30 a 30-question tool was used to assess the overall quality of life (QoL) in cancer patients. It included 30 items resulting in 5 functional scales (physical, role, emotional, cognitive, and social functioning), 1 Global health status (GHS) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall QoL. Scores were transformed to a 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms.
| Score on scale | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|
| Week 4 | 3.79 (0.33 to 7.25) | 2.07 (-1.39 to 5.53) |
| Week 8 | 4.04 (0.50 to 7.58) | 3.93 (0.44 to 7.42) |
| Week 12 | 6.35 (2.74 to 9.96) | 2.77 (-0.82 to 6.37) |
| Week 16 | 9.92 (6.25 to 13.60) | 1.54 (-2.10 to 5.17) |
| Week 20 | 6.83 (3.01 to 10.65) | 3.87 (0.27 to 7.47) |
| Week 24 | 0.69 (-5.40 to 6.79) | 0.30 (-3.37 to 3.98) |
| Week 28 | 3.30 (-0.90 to 7.51) | 2.14 (-4.41 to 8.69) |
| Week 32 | -3.14 (-11.77 to 5.49) | -4.92 (-8.82 to -1.03) |
| Week 36 | -10.25 (-21.95 to 1.45) | -12.59 (-20.06 to -5.13) |
| Week 40 | 2.09 (-7.49 to 11.68) | -5.39 (-9.34 to -1.43) |
| Week 44 | 1.57 (-9.46 to 12.59) | -9.55 (-17.19 to -1.90) |
| Week 48 | -2.82 (-8.98 to 3.34) | -7.99 (-12.03 to -3.95) |
| Week 52 | -1.69 (-9.28 to 5.90) | -5.56 (-12.58 to 1.46) |
| Week 56 | -1.88 (-10.00 to 6.24) | -6.77 (-10.89 to -2.64) |
| Week 60 | -2.62 (-10.99 to 5.75) | -9.23 (-16.12 to -2.34) |
| Week 64 | -3.55 (-13.13 to 6.04) | -10.36 (-14.61 to -6.12) |
| Week 68 | 0.84 (-9.63 to 11.30) | -5.96 (-11.90 to -0.03) |
| Week 72 | -0.44 (-7.55 to 6.67) | -11.80 (-16.16 to -7.45) |
| Week 76 | -5.08 (-14.68 to 4.51) | -8.91 (-15.07 to -2.75) |
| Week 80 | -6.00 (-12.96 to 0.97) | -10.79 (-15.07 to -6.51) |
| Week 84 | -17.23 (-28.87 to -5.58) | -10.39 (-16.63 to -4.14) |
| Week 88 | -6.71 (-16.34 to 2.91) | -9.83 (-14.08 to -5.57) |
| Week 92 | -7.43 (-19.78 to 4.92) | -12.11 (-18.43 to -5.78) |
| Week 96 | -5.75 (-13.87 to 2.37) | -8.56 (-13.16 to -3.95) |
The SF-36 Health Survey was a generic measure of health status. The SF-36 consisted of 36 questions that yield an eight-scale (physical functioning, role-physical, bodily pain, general health, vitality, social functioning, role-emotional, and mental health) profile of functional health and well-being, as well as 2 physical and mental health summary measures and a preference-based health utility index. The physical component summary (PCS), the mental component summary (MCS), and the 8 domain scores range from zero (0) to 100, with higher scores representing higher level of functioning.
| Score on scale | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|
| Week 4 | -0.43 (-1.95 to 1.09) | -0.19 (-1.71 to 1.34) |
| Week 8 | -1.09 (-2.64 to 0.46) | -1.42 (-2.96 to 0.12) |
| Week 12 | -1.86 (-3.44 to -0.28) | -0.17 (-1.74 to 1.40) |
| Week 16 | -3.15 (-4.76 to -1.54) | -0.35 (-1.94 to 1.23) |
| Week 20 | -2.36 (-4.04 to -0.68) | -0.42 (-1.99 to 1.16) |
| Week 24 | -1.84 (-4.50 to 0.82) | -0.60 (-2.20 to 1.01) |
| Week 28 | -3.26 (-5.10 to -1.42) | -0.93 (-3.74 to 1.88) |
| Week 32 | 0.19 (-3.51 to 3.89) | 0.61 (-1.09 to 2.31) |
| Week 36 | -0.45 (-5.47 to 4.57) | 1.22 (-2.05 to 4.49) |
| Week 40 | -0.56 (-4.67 to 3.54) | 2.02 (0.30 to 3.74) |
| Week 44 | 1.30 (-3.70 to 6.30) | 1.55 (-1.73 to 4.82) |
| Week 48 | 0.26 (-2.39 to 2.91) | 2.18 (0.41 to 3.94) |
| Week 52 | 0.69 (-2.57 to 3.94) | 1.33 (-1.73 to 4.39) |
| Week 56 | -0.35 (-3.83 to 3.13) | 0.91 (-0.88 to 2.71) |
| Week 60 | 2.20 (-1.39 to 5.79) | 1.32 (-1.64 to 4.28) |
| Week 64 | -2.00 (-6.28 to 2.28) | 2.74 (0.90 to 4.58) |
| Week 68 | 0.68 (-3.81 to 5.17) | 1.25 (-1.32 to 3.83) |
| Week 72 | -1.21 (-4.26 to 1.84) | 2.03 (0.14 to 3.92) |
| Week 76 | 1.05 (-3.07 to 5.17) | 0.12 (-2.56 to 2.80) |
| Week 80 | 0.47 (-2.58 to 3.52) | 2.32 (0.44 to 4.20) |
| Week 84 | 3.21 (-1.77 to 8.19) | 1.56 (-1.12 to 4.25) |
| Week 88 | 2.12 (-2.35 to 6.59) | 2.57 (0.72 to 4.42) |
| Week 92 | -2.50 (-7.78 to 2.78) | 1.31 (-1.40 to 4.02) |
| Week 96 | -0.03 (-3.61 to 3.55) | 2.96 (0.96 to 4.96) |
The EORTC-QLQ-C30 a 30-question tool was used to assess the overall QoL in cancer patients. It included 30 items resulting in 5 functional scales (physical, role, emotional, cognitive, and social functioning), 1 GHS scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The questionnaire includes 28 items with 4-point Likert type responses from "1-not at all" to "4-very much" to assess functioning and symptoms; 2 items with 7-point Likert scales (1= poor and 7= excellent) for global health and overall QoL. Scores were transformed to a 0 to 100 scale, with higher scores representing better GHS, better functioning, and more symptoms.
| Score on scale | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|
| Week 4 | -3.02 (-5.89 to -0.14) | -2.72 (-5.59 to 0.16) |
| Week 8 | -4.15 (-7.09 to -1.21) | -3.83 (-6.73 to -0.93) |
| Week 12 | -6.00 (-9.01 to -3.00) | -1.70 (-4.70 to 1.29) |
| Week 16 | -7.17 (-10.23 to -4.11) | -2.75 (-5.78 to 0.28) |
| Week 20 | -5.46 (-8.65 to -2.27) | -2.53 (-5.52 to 0.47) |
| Week 24 | -4.26 (-9.43 to 0.92) | -0.76 (-3.83 to 2.31) |
| Week 28 | -3.81 (-7.34 to -0.29) | -1.96 (-7.53 to 3.61) |
| Week 32 | 3.03 (-4.33 to 10.39) | 1.36 (-1.90 to 4.62) |
| Week 36 | 2.97 (-7.02 to 12.97) | 3.09 (-3.27 to 9.45) |
| Week 40 | -6.13 (-14.31 to 2.05) | 5.10 (1.79 to 8.41) |
| Week 44 | -1.37 (-10.79 to 8.05) | 0.16 (-6.36 to 6.68) |
| Week 48 | -0.71 (-5.94 to 4.52) | 6.79 (3.40 to 10.17) |
| Week 52 | -0.17 (-6.63 to 6.30) | 8.61 (2.64 to 14.59) |
| Week 56 | 3.62 (-3.30 to 10.54) | 4.02 (0.56 to 7.49) |
| Week 60 | 2.33 (-4.80 to 9.47) | 5.85 (-0.02 to 11.71) |
| Week 64 | -5.49 (-13.67 to 2.70) | 8.27 (4.70 to 11.83) |
| Week 68 | 6.19 (-2.75 to 15.14) | 4.95 (-0.08 to 9.99) |
| Week 72 | -4.26 (-10.31 to 1.79) | 8.94 (5.27 to 12.60) |
| Week 76 | 2.00 (-6.19 to 10.19) | 10.34 (5.11 to 15.57) |
| Week 80 | 4.13 (-1.79 to 10.06) | 7.05 (3.45 to 10.65) |
| Week 84 | 3.69 (-6.26 to 13.64) | 6.85 (1.54 to 12.15) |
| Week 88 | -2.95 (-11.16 to 5.26) | 7.59 (4.01 to 11.16) |
| Week 92 | 3.18 (-7.39 to 13.74) | 8.08 (2.70 to 13.45) |
| Week 96 | 6.54 (-0.38 to 13.47) | 8.03 (4.15 to 11.91) |
Collected over All cause mortality: From baseline (Day -28) up to 7.1 years; Serious and Other AEs: For CyBorD: From start of treatment (Day 1) up to 30 days after last dose of study drug ( up to 8.33 months). Daratumumab plus CyBorD: From start of treatment (Day 1) up to 30 days after last dose of study drug ( up to 27.7 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Run-In: Daratumumab Plus CyBorD | 11/28 (39.3%) | 12/28 (42.9%) | 27/28 (96.4%) |
| CyBorD | 67/193 (34.7%) | 68/188 (36.2%) | 181/188 (96.3%) |
| Daratumumab Plus CyBorD | 47/195 (24.1%) | 91/193 (47.2%) | 184/193 (95.3%) |
| Event | Run-In: Daratumumab Plus CyBorD | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|---|
| FallInjury, poisoning and procedural complications | 3/28 | 0/188 | 0/193 |
| Acute Kidney InjuryRenal and urinary disorders | 3/28 | 1/188 | 3/193 |
| Cardiac FailureCardiac disorders | 0/28 | 8/188 | 14/193 |
| PneumoniaInfections and infestations | 2/28 | 9/188 | 14/193 |
| CellulitisInfections and infestations | 2/28 | 1/188 | 2/193 |
| Cardiac ArrestCardiac disorders | 0/28 | 3/188 | 8/193 |
| SepsisInfections and infestations | 0/28 | 0/188 | 7/193 |
| AnaemiaBlood and lymphatic system disorders | 1/28 | 1/188 | 0/193 |
| Cardiac Failure CongestiveCardiac disorders | 1/28 | 2/188 | 1/193 |
| DiarrhoeaGastrointestinal disorders | 1/28 | 4/188 | 3/193 |
| Event | Run-In: Daratumumab Plus CyBorD | CyBorD | Daratumumab Plus CyBorD |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 19/28 | 55/188 | 69/193 |
| FatigueGeneral disorders | 16/28 | 52/188 | 55/193 |
| Oedema PeripheralGeneral disorders | 14/28 | 66/188 | 71/193 |
| AnaemiaBlood and lymphatic system disorders | 13/28 | 44/188 | 49/193 |
| DizzinessNervous system disorders | 13/28 | 26/188 | 31/193 |
| LymphopeniaBlood and lymphatic system disorders | 12/28 | 28/188 | 37/193 |
| ConstipationGastrointestinal disorders | 12/28 | 54/188 | 70/193 |
| NauseaGastrointestinal disorders | 12/28 | 51/188 | 55/193 |
| Upper Respiratory Tract InfectionInfections and infestations | 10/28 | 21/188 | 50/193 |
| HyperglycaemiaMetabolism and nutrition disorders | 10/28 | 7/188 | 12/193 |
| Age, Continuous(years) | Run-In: Daratumumab Plus CyBorD | CyBorD | Daratumumab Plus CyBorD | Total |
|---|---|---|---|---|
| Mean | 64.8 ± 11.2 | 64 ± 9.66 | 62.2 ± 10.16 | 63.2 ± 10.03 |
| Sex/Gender, Customized(Participants) | Run-In: Daratumumab Plus CyBorD | CyBorD | Daratumumab Plus CyBorD | Total |
|---|---|---|---|---|
| Female | 11 | 76 | 87 | 174 |
| Male | 16 | 117 | 108 | 241 |
| Undifferentiated Sex | 1 | 0 | 0 | 1 |
| Ethnicity (NIH/OMB)(Participants) | Run-In: Daratumumab Plus CyBorD | CyBorD | Daratumumab Plus CyBorD | Total |
|---|---|---|---|---|
| Hispanic or Latino | 1 | 13 | 9 | 23 |
| Not Hispanic or Latino | 26 | 176 | 179 | 381 |
| Unknown or Not Reported | 1 | 4 | 7 | 12 |
| Race (NIH/OMB)(Participants) | Run-In: Daratumumab Plus CyBorD | CyBorD | Daratumumab Plus CyBorD | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 1 | 3 |
| Asian | 0 | 34 | 30 | 64 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 0 | 1 |
| Black or African American | 2 | 7 | 6 | 15 |
| White | 25 | 143 | 151 | 319 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 1 | 5 | 7 | 13 |
| Region of Enrollment(Participants) | Run-In: Daratumumab Plus CyBorD | CyBorD | Daratumumab Plus CyBorD | Total |
|---|---|---|---|---|
| AUSTRALIA | 0 | 15 | 12 | 27 |
| BELGIUM | 0 | 1 | 2 | 3 |
| BRAZIL | 0 | 7 | 4 | 11 |
| CANADA | 0 | 10 | 9 | 19 |
| CHINA | 0 | 6 | 6 | 12 |
| DENMARK | 0 | 1 | 1 | 2 |
| FRANCE | 0 | 22 | 16 | 38 |
| GERMANY | 0 | 11 | 8 | 19 |
| GREECE | 0 | 11 | 16 | 27 |
| HUNGARY | 0 | 2 | 2 | 4 |
| ISRAEL | 0 | 5 | 6 | 11 |
| ITALY | 0 | 5 | 4 | 9 |
| JAPAN | 0 | 13 | 15 | 28 |
| MEXICO | 0 | 1 | 1 | 2 |
| NETHERLANDS | 0 | 4 | 7 | 11 |
| POLAND | 0 | 2 | 2 | 4 |
| SOUTH KOREA | 0 | 12 | 8 | 20 |
| SPAIN | 0 | 11 | 21 | 32 |
| SWEDEN | 0 | 2 | 1 | 3 |
| TURKEY | 0 | 7 | 10 | 17 |
| UNITED KINGDOM | 0 | 4 | 4 | 8 |
| UNITED STATES | 28 | 41 | 40 | 109 |
| Weight group in Kilograms (Kg)(Participants) | Run-In: Daratumumab Plus CyBorD | CyBorD | Daratumumab Plus CyBorD | Total |
|---|---|---|---|---|
| <=65 kg | 5 | 74 | 62 | 141 |
| >65 to 85 kg | 12 | 74 | 96 | 182 |
| >85 kg | 11 | 45 | 37 | 93 |
| Baseline Major Organ Involvement(Participants) | Run-In: Daratumumab Plus CyBorD | CyBorD | Daratumumab Plus CyBorD | Total |
|---|---|---|---|---|
| Baseline Organ Involvement: Heart | 17 | 137 | 140 | 294 |
| Baseline Organ Involvement: Kidney | 19 | 114 | 115 | 248 |
| Baseline Organ Involvement: Liver | 4 | 16 | 15 | 35 |
| Number of Organs Involved(organs) | Run-In: Daratumumab Plus CyBorD | CyBorD | Daratumumab Plus CyBorD | Total |
|---|---|---|---|---|
| Mean | 2.0 ± 0.881 | 2.0 ± 1.03 | 2.0 ± 0.97 | 2.0 ± 0.99 |
3 further baseline measures are reported on the registry.
Showing the first 100 of 140 sites across 22 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2017 to primary completion in Feb 2020, 28 months.
Results were first posted in Mar 2021, 1 year after primary completion.
Of 25 phase 3 interventional studies under Amyloidosis, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 74. This study's 28 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Daratumumab
Janssen Research & Development, LLC →